LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

33.62 -7.23

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

33.45

Massimo

33.95

Metriche Chiave
By Trading Economics
Entrata	7.3M -123M
Vendite	3.7M 3.9M
EPS	-1.29
Margine di Profitto	-3,161.261
Dipendenti	594
EBITDA	20M -122M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+161.36% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-855M 3.6B
Apertura precedente	40.85
Chiusura precedente	33.62

Notizie sul Sentiment di mercato

By Acuity

44%

56%

140 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 mar 2026, 17:33 UTC

Principali Notizie su Eventi

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mar 2026, 17:00 UTC

Principali Notizie su Eventi

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mar 2026, 16:03 UTC

Principali Notizie su Eventi

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mar 2026, 14:50 UTC

I principali Market Mover

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mar 2026, 14:37 UTC

Acquisizioni, Fusioni, Takeovers

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mar 2026, 14:29 UTC

Principali Notizie su Eventi

EU Finance Ministers Tally Economic Hit of Iran War -- Update

28 mar 2026, 13:32 UTC

Utili

Berkshire Hathaway Just Notched an 8-Day Losing Streak. It's a Good Time to Get Exposure to the Conglomerate. -- Barrons.com

28 mar 2026, 08:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

28 mar 2026, 08:00 UTC

Utili

It Was a Busy Week for Videogames. Keep An Eye on These Stocks. -- Barrons.com

27 mar 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

27 mar 2026, 19:16 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mar 2026, 19:07 UTC

Discorsi di Mercato

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mar 2026, 19:04 UTC

Discorsi di Mercato

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mar 2026, 19:03 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 19:02 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mar 2026, 18:12 UTC

Discorsi di Mercato

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mar 2026, 17:36 UTC

Principali Notizie su Eventi

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mar 2026, 17:34 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mar 2026, 17:29 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mar 2026, 16:38 UTC

Discorsi di Mercato

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mar 2026, 16:32 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mar 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

27 mar 2026, 15:43 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mar 2026, 15:25 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 15:25 UTC

Discorsi di Mercato

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mar 2026, 15:00 UTC

Principali Notizie su Eventi

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mar 2026, 15:00 UTC

Principali Notizie su Eventi

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mar 2026, 15:00 UTC

Principali Notizie su Eventi

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mar 2026, 14:36 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mar 2026, 14:26 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

161.36% in crescita

Previsioni per 12 mesi

Media 88 USD 161.36%

Alto 97 USD

Basso 67 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

140 / 349 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.